Search clinical trials for: ASCI (Antigen-Specific Cancer Immunotherapeutic)

Total 86717 results

Jules Bordet Institute

Unknown

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia (ASCI)

Effects of Immunotherapy | Acute Myelogenous Leukemia | Myeloid Leukemia in Remission

Belgium
GlaxoSmithKline

Terminated

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Australia, Canada, Netherlands, Finland, Taiwan, Czechia, Estonia, Spain, Argentina, Belgium, France, Sweden, Germany, Israel, Italy, Korea, Republic of, Singapore, Ukraine, United Kingdom, Austria, Ireland, Thailand, C... and more
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Melanoma

France, Italy, Germany, Netherlands, Switzerland, United Kingdom, Austria, Australia
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center; Fox Chase Cancer Center; GlaxoSmithKline and other collaborators

Completed

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Multiple Myeloma

United States
GlaxoSmithKline

Completed

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Melanoma

France, Belgium
GlaxoSmithKline

Terminated

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Melanoma

Norway, Argentina, Greece
GlaxoSmithKline

Completed

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (PREDICT)

Melanoma

United States, Spain, Germany, France, Poland, Italy, Ireland, Russian Federation
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Leukaemia, Myelocytic, Acute

Germany, France, United States
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Renal Cell Carcinoma

Canada, United States
GlaxoSmithKline

Completed

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Melanoma

Germany, Czechia, France, Italy, Russian Federation, Poland
McGill University Health Centre/Research Institute...
Université de Montréal; Argos Therapeutics

Completed

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.

Acquired Immunodeficiency Syndrome | HIV Seropositivity

Canada
GlaxoSmithKline

Completed

A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

Neoplasms, Breast

Belgium, United States, Australia, France, Italy
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Leukaemia, Myelocytic, Acute

United States, France
GlaxoSmithKline

Terminated

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

Lung Cancer, Non-Small Cell

United States, France, Germany, Russian Federation, Poland, Italy
Duke University
Immunotope

Completed

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

Breast Cancer

United States
Brigham and Women's Hospital

Completed

Personalized Immunotherapeutic for Antibiotic-resistant Infection

Infection | Immune Deficiency | Hypogammaglobulinemia | Septic Arthritis | Mycoplasma Hominis

United States
GlaxoSmithKline

Terminated

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Melanoma

United States, Australia, Spain, Taiwan, Bulgaria, Estonia, Germany, Belgium, France, Sweden, Israel, Poland, Italy, Czechia, Switzerland, Korea, Republic of, Ireland, Canada, Argentina, Netherlands, Russian Federation, Ukraine, Aus... and more
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
GlaxoSmithKline

Terminated

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

Melanoma

Belgium, France
Fudan University

Unknown

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

NSCLC Patients

China
Cliniques universitaires Saint-Luc- Université...

Active, not recruiting

Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy (Plasma-Target)

Cancer

Belgium
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Colorectal Cancer

Japan
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
GlaxoSmithKline

Terminated

Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

Canada, Italy, Belgium, France, Germany, United Kingdom
Institut Bergonié
French Sarcoma Group

Recruiting

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group (BCB-Sarcomes)

Sarcoma

France
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Lung Cancer | Non Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
MedImmune LLC

Active, not recruiting

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Advanced and/or Metastatic Sarcoma

United States
Gary Onik MD

Completed

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. (NIRPA)

Adenocarcinoma

United States
Vaccitech (UK) Limited

Recruiting

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Prostate Cancer

United States
National Institute of Allergy and Infectious Diseases...
Regeneron Pharmaceuticals

Withdrawn

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

Hepatitis B Virus

United States, Thailand, Canada, Brazil
Michael Morse, MD
Immunotope

Completed

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Epithelial Ovarian, Tubal or Peritoneal Cancer

United States
University of Colorado, Denver
The Leona M. and Harry B. Helmsley Charitable Trust; Nova Immunotherapeutics...

Recruiting

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (MER3101)

Type 1 Diabetes Mellitus

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Active, not recruiting

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Hepatocellular Carcinoma | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Microsatellite Instability-High

United States, Canada
RAPHAS

Enrolling by invitation

Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients

Rhinitis, Allergic | Mite Allergy | House Dust Mite Rhinitis

Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

United States
Argos Therapeutics

Completed

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

HIV Infections

Canada, United States
Panacela Labs LLC

Completed

Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

Prostate Cancer

Russian Federation
National Institute of Allergy and Infectious Diseases...
Regeneron Pharmaceuticals

Terminated

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

HIV Infections

United States
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

HIV Infections

United States
National Cancer Institute (NCI)

Recruiting

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma (SCC)

United States
AbbVie

Terminated

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Cellid Co., Ltd.

Completed

Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care (BVAC-B)

Stomach Neoplasms

Korea, Republic of
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Renal Cell Carcinoma

United States, Canada
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb; Bayer; University of Michigan; Big Ten Cancer Research Consortium

Active, not recruiting

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Indolent Lymphoma

United States
Altor BioScience

Completed

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Advanced Pancreatic Cancer

United States
Amgen Research (Munich) GmbH

Completed

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cryoablation for the Treatment of Metastatic Cancer

Metastatic Malignant Neoplasm

United States
Panacela Labs LLC

Unknown

A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer

Prostate Cancer

Russian Federation
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
GlaxoSmithKline

Terminated

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (INDUCT)

Neoplasms, Breast

United States, Belgium, United Kingdom, Germany, Russian Federation, Italy, France

3

Subscribe